<DOC>
	<DOCNO>NCT00430261</DOCNO>
	<brief_summary>This open-label study new oral drug advance stage ( IIIB IV ) lung cancer . The cancer must EITHER bronchoalveolar carcinoma ( BAC ) type , patient never-smoker ( less 100 cigarette lifetime ) cancer type adenocarcinoma .</brief_summary>
	<brief_title>Phase II Trial Sunitinib BAC Never-Smokers With Any Lung Adenocarcinoma</brief_title>
	<detailed_description>To participate study , patient must disease measure CT scan . Brain metastases OK stable . Pregnant and/or nursing woman may participate . This drug approve FDA treatment advance renal cell cancer certain type stomach/intestinal cancer . Its efficacy lung cancer currently unknown . Common side effect include fatigue , nausea , diarrhea , skin reaction , decrease blood count .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Bronchoalveolar carcinoma disease measurable CAT scan Any lung adenocarcinoma neversmoker ( le 100 cigarette lifetime ) disease measurable CAT scan Stage IIIB IV Uncontrolled hypertension Unstable brain metastasis Pregnant/nursing woman Uncontrolled thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>bronchoalveolar carcinoma</keyword>
	<keyword>BAC</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>lung cancer</keyword>
	<keyword>oral</keyword>
	<keyword>Stage IIIB IV lung cancer</keyword>
	<keyword>Any bronchoalveolar carcinoma ( BAC )</keyword>
	<keyword>Any adenocarcinoma never-smoker</keyword>
</DOC>